Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery



Status:Completed
Conditions:Peripheral Vascular Disease, Diabetes
Therapuetic Areas:Cardiology / Vascular Diseases, Endocrinology
Healthy:No
Age Range:45 - 75
Updated:3/1/2014
Start Date:March 2013
End Date:May 2014
Contact:Kristin Newby, MD
Email:kristin.newby@dm.duke.edu
Phone:919-668-8805

Use our guide to learn which trials are right for you!

Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Individuals with type 2 diabetes mellitus (T2DM) are at increased risk for cardiovascular
events (for example, heart attack) and the risk is related to one's overall control of blood
glucose levels. In this study the investigators will measure the effects of saxagliptin,
compared to placebo, before, during, and after coronary artery bypass graft (CABG) surgery.
The investigators will use samples of the patients' blood and tissue to measure and evaluate
indicators of your body's response to the treatment. This study is being done to evaluate
the effect of saxagliptin on biomarkers of the heart to help us understand whether reducing
or controlling a person's blood glucose levels during and after CABG surgery will produce
better clinical outcomes (for example, better heart health).

This study is a randomized, double-blind, placebo-controlled clinical trial to evaluate the
effect of saxagliptin on cardiac biomarkers of myocardial necrosis, cardiac function,
inflammation, and apoptosis in subjects with Type 2 diabetes mellitus (T2DM) undergoing CABG
surgery (on pump, via a median sternotomy approach) as an integrated measure of the
potential mechanistic effects of saxagliptin on prevention of CV outcomes. Approximately 74
subjects will be randomized and complete the study.

Inclusion Criteria:

- Known diagnosis of type 2 diabetes mellitus (T2DM) with glycosylated hemoglobin
(HbA1c) between 6.5% and 10%, inclusive.

- Stable doses of oral antihyperglycemic agents for at least 2 months

- Stable dose of chronic insulin therapy for at least 2 months

- HbA1c documented within 3 months before study enrollment

- Planned first elective coronary artery bypass graft (CABG) surgery

Exclusion Criteria:

- Elevated Creatine Kinase-MB or troponin level above the 99th percentile at screening

- Receiving incretin therapy or having received incretin therapy within the previous 2
months

- Type 1 DM or a history of ketoacidosis

- Women who are pregnant or breastfeeding

- Known end-stage Kidney disease

- Known sensitivity or intolerance to saxagliptin or DPP-4 inhibitor

- Clinically apparent liver disease

- History of pancreatitis
We found this trial at
10
sites
Birmingham, Alabama 35211
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
550 Peachtree St NE
Atlanta, Georgia 30308
(404) 686-4411
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Birmingham, Alabama 35213
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Charleston, West Virginia 25304
?
mi
from
Charleston, WV
Click here to add this to my saved trials
Durham, North Carolina 27710
?
mi
from
Durham, NC
Click here to add this to my saved trials
Fort Smith, Arkansas 72901
?
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Huntsville, Alabama 35801
?
mi
from
Huntsville, AL
Click here to add this to my saved trials
Little Rock, Arkansas 72205
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Palo Alto, California 94304
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Richmond, Virginia 23225
?
mi
from
Richmond, VA
Click here to add this to my saved trials